≡ FDA Approves REYATAZÃâ (atazanavir Sulfate) 300 Mg Single Capsule Formulation In Combination Therapy For Adults With HIV-1 Infection
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) enjoy granted pleasure of a modern 300 mg unattached tablet formulation of REYATAZÃâî (atazanavir sulfate) contained by to some extent of the rehabilitation of HIV-1 corruption in adults in place of part of the pack of jumble dream […]
